Status:
COMPLETED
Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine
Lead Sponsor:
Sanofi Pasteur, a Sanofi Company
Conditions:
Meningitis
Meningococcal Disease
Eligibility:
All Genders
Brief Summary
To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
Eligibility Criteria
Inclusion
- Receipt of Menactra vaccine during the study period.
Exclusion
- None
Key Trial Info
Start Date :
July 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
62626 Patients enrolled
Trial Details
Trial ID
NCT00254995
Start Date
July 1 2005
End Date
May 1 2013
Last Update
April 19 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oakland, California, United States, 94612